Each year 5.3 million Americans are living with a traumatic brain injury (TBI)-related disability and another 1.4 million individuals suffer from a TBI. The objective of this project was to evaluate a novel nanoparticle system to address the underlying pathology following TBI. Specifically, researchers used RNA seq to analyze global gene expression trends obtained from
Faculty Mentor: Sarah Stabenfeldt
Optimizing Recombinant Protein Production for Domain Antibodies: Proof-of-Concept
Recent studies in traumatic brain injury (TBI) have found a temporal window where nanometer scale therapeutics can cross the blood-brain barrier into the parenchyma. Development of recombinant antibody production is attractive due to its wide range of biological applications in diagnostic and therapeutic use. However, the production pipeline for high yield, purified, and consistent bioactive
Nanoparticle Delivery through a Resection-Disrupted Blood Brain Barrier for the Treatment of Glioblastoma
The standard of care for Glioblastoma (GBM) is surgical resection however, tumors reoccur within a few centimeters from the resection cavity behind an intact blood-brain-barrier (BBB). This project examined the spatiotemporal disruption of the BBB by surgical resection to deliver nanoparticles (NPs) to the peri-resection tissue (PRT). When NPs were administered immediately after surgery, they
Human Neural Progenitor Cell Transplantation Sustainment and Maturation with Immunodeficient Mice
This project addresses the feasibility of human neural progenitor cell (hNPC) transplantation into the striatum of immunodeficient mice. Injections of hNPCs and hNPCs encapsulated in a hyaluronic acid-laminin based hydrogel (HA-Lm gel) were performed. Immunohistochemistry (IHC) was performed 7 and 14 days post-injection for key cell lineage specific markers. These markers will allow for quantitative
